• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Singular Genomics Systems Inc.

    2/25/25 9:18:06 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $OMIC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)


    Singular Genomics Systems, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    82933R308

    (CUSIP Number)


    David Clark
    Deerfield Management Company, L.P., 345 Park Avenue South, 12 Floor
    New York, NY, 10010
    212-551-1600


    Elliot Press
    Deerfield Management Company, L.P., 345 Park Avenue South, 12 Floor
    New York, NY, 10010
    212-551-1600


    Jonathan D. Weiner, Esq.
    Katten Muchin Rosenman LLP, 50 Rockefeller Plaza
    New York, NY, 10020
    212-940-8800


    Mark D. Wood, Esq.
    Katten Muchin Rosenman LLP, 50 Rockefeller Plaza
    New York, NY, 10020
    212-940-8800

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    02/21/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    82933R308


    1 Name of reporting person

    Deerfield Mgmt IV, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,000.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,000.00
    11Aggregate amount beneficially owned by each reporting person

    1,000.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    100 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Comprised of shares of common stock held by Singular Genomics Parent, LLC.


    SCHEDULE 13D

    CUSIP No.
    82933R308


    1 Name of reporting person

    Deerfield Private Design Fund IV, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,000.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,000.00
    11Aggregate amount beneficially owned by each reporting person

    1,000.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    100 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Comprised of shares of common stock held by Singular Genomics Parent, LLC.


    SCHEDULE 13D

    CUSIP No.
    82933R308


    1 Name of reporting person

    Deerfield Management Company, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,000.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,000.00
    11Aggregate amount beneficially owned by each reporting person

    1,000.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    100 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Comprised of shares of common stock held by Singular Genomics Parent, LLC.


    SCHEDULE 13D

    CUSIP No.
    82933R308


    1 Name of reporting person

    James E. Flynn
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,000.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,000.00
    11Aggregate amount beneficially owned by each reporting person

    1,000.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    100 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Comprised of shares of common stock held by Singular Genomics Parent, LLC.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.0001 per share
    (b)Name of Issuer:

    Singular Genomics Systems, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    345 Park Avenue South, 12 Floor, New York, NEW YORK , 10010.
    Item 1 Comment:
    This Amendment No. 3 (this "Amendment") to Schedule 13D amends the Schedule 13D, as amended by Amendment Nos. 1 and 2 thereto (as amended, the "Schedule 13D"), filed by (i) Deerfield Mgmt IV, L.P. ("Deerfield Mgmt IV"), (ii) Deerfield Private Design Fund IV, L.P. ("Deerfield Private Design Fund IV"), (iii) Deerfield Management Company, L.P. ("Deerfield Management"), and (iv) James E. Flynn, a natural person ("Flynn" and collectively with Deerfield Mgmt IV, Deerfield Private Design Fund IV, Deerfield Management and Flynn, the "Reporting Persons"), with respect to the common stock, par value $0.0001 per share, of Singular Genomics Systems, Inc. Capitalized terms used and not otherwise defined in this Amendment have the meanings ascribed to them in the Schedule 13D.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Item 3 of the Schedule 13D is hereby amended by adding the following: The information set forth in Item 4 of Amendment No. 3 to the Schedule 13D is incorporated by reference into this Item 3.
    Item 4.Purpose of Transaction
     
    Item 4 of the Schedule 13D is hereby amended by adding the following: Completion of the Merger As previously disclosed, on December 22, 2024, Singular Genomics Parent, LLC ("Parent"), which was then a direct wholly-owned subsidiary of Deerfield Private Design Fund IV, and Saturn Merger Sub, Inc., a direct wholly-owned subsidiary of Parent ("Merger Sub"), entered into the Merger Agreement with the Company. On February 19, 2025, the Company held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the holders of the Common Stock voted to adopt the Merger Agreement and to approve the transactions contemplated thereby, including the Merger (as defined below). On February 21, 2025, pursuant to the Merger Agreement, Merger Sub merged with and into the Company (the "Merger"). The Company was the surviving corporation in the Merger and, as a result, is now a wholly owned subsidiary of Parent. Deerfield Private Design Fund IV is entitled to appoint managers representing a majority of the voting power of the board of managers of Parent. At the effective time of the Merger (the "Effective Time"), each share of Common Stock issued and outstanding as of immediately prior to the Effective Time (other than the Excluded Shares, including shares of Common Stock that were contributed to Parent by the Rollover Stockholders (as defined below)) was cancelled and automatically converted into the right to receive $20.00 in cash, without interest, net of any applicable withholding taxes (the "Merger Consideration"). The shares of Common Stock held by Parent (including shares of Common Stock underlying Series A Preferred Stock) immediately prior to the Effective Time were cancelled as a result of the Merger (without payment of any Merger Consideration), and each share of the common stock of Merger Sub issued and outstanding immediately prior to the Effective Time (all of which shares were held by Parent) was converted into and exchanged for one share of Common Stock. Vested Stock Options were cancelled at the Effective Time and converted into the right to receive an amount in cash determined by multiplying (i) the excess, if any, of the Merger Consideration over the applicable exercise price of such Vested Stock Option by (ii) the number of Company Shares subject to such Vested Stock Option (less all applicable deductions and withholdings). Company stock options that were not Vested Stock Options were cancelled and forfeited without consideration or payment. Unvested RSUs and Vested RSUs that were held by Designated Continuing Employees (each, a "Designated Continuing Employee RSU") were cancelled at the Effective Time and converted into restricted stock units (each, an "Assumed RSU") and settled in Class B Units of Parent ("Parent Class B Units"), on the same terms and conditions (except with respect to the employment terms applicable to the holders of Designated Continuing Employee RSUs with the Surviving Corporation), including applicable vesting requirements, as applied to each such Designated Continuing Employe RSU immediately prior to the Effective Time, except that the number of Parent Class B Units underlying each such Assumed RSU equals 20. Vested RSUs held by persons who are not Designated Continuing Employees (each, an "Other Vested RSU") were cancelled at the Effective Time and converted into the right to receive an amount in cash (without interest) equal to (i) the Merger Consideration multiplied by (ii) the number of shares of Common Stock subject to such other Vested RSU (less all applicable deductions and withholdings). Unvested RSUs that were held by persons who were not Designated Continuing Employees were cancelled and forfeited without consideration or payment. In accordance with the terms of the Merger Agreement, at the Effective Time, each of the directors of the Company resigned and, immediately following the Effective Time, the Company's board of directors was re-constituted to consist of the following directors: Andrew ElBardissi, Avi Kometz, Bryan Sendrowski, Joshua Stahl, Jason Meyers and Andrew Spaventa. Further, immediately following the Effective Time, Joshua Stahl was appointed as the Company's Chief Executive Officer and Jason Myers was appointed as the Company's President. Delisting As a result of the Merger, the Common Stock is no longer listed or traded on Nasdaq or on any other stock exchange or stock market. The Company intends to file with the SEC a Form 15 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), requesting the deregistration of the Common Stock and the suspension of the Company's reporting obligations under Sections 13 and 15(d) of the Exchange Act. Rollover Agreements On the closing date of the Merger and immediately prior to the Effective Time, certain stockholders of the Company, including Deerfield Private Design Fund IV (collectively, the "Rollover Stockholders"), separately entered into Rollover Agreements, each dated February 21, 2025, with Parent, pursuant to which each such stockholder contributed, assigned, and transferred to Parent certain Company Shares (including all of the Company Shares previously held by Deerfield Private Design Fund IV). In exchange for such contribution, each Rollover Stockholder (other than Deerfield Private Design Fund IV) received Class B Units in Parent. Debt Financing As previously disclosed, in connection with the execution of the Merger Agreement, Deerfield Private Design Fund IV committed to providing debt financing to Parent, subject to customary terms and conditions, to finance the aggregate cash consideration payable in connection with the Merger and certain related fees and expenses. In connection with the closing of the Merger, Deerfield Private Design Fund IV entered into a Credit Agreement (the "Credit Agreement") with Parent and Merger Sub (in such capacities, the "Borrowers"), pursuant to which Deerfield Private Design Fund IV committed to provide a term loan to the Borrowers in an aggregate amount of up to $37.5 million. Proceeds from such loan in the amount of approximately $37 million were deposited with the paying agent under the Merger Agreement for further payment to the Company's stockholders pursuant to the Merger Agreement. By virtue of the Merger, the Company (as the surviving corporation in the Merger) became a borrower under the Credit Agreement. The loan is prepayable at any time. Deerfield Private Design Fund IV utilized its working capital to provide the loans made pursuant to the Credit Agreement. The Reporting Persons may, at any time and from time to time, formulate purposes, plans or proposals regarding the Company, or any other actions that could involve one or more of the types of transactions or have one or more of the results described in paragraphs (a) through (j) of Item 4 of Schedule 13D. Further, as the beneficial owners of 100% of the outstanding Common Stock, the Reporting Persons have the ability to cause the Company to effectuate any such actions or transactions, to the extent available to the Company.
    Item 5.Interest in Securities of the Issuer
    (a)
    Item 5 of the Schedule 13D is hereby amended and restated in its entirety to read as follows: (1) Deerfield Mgmt IV Number of shares: 1,000 (comprised of shares held by Parent) Percentage of shares: 100% (2) Deerfield Management Number of shares: 1,000 (comprised of shares, held by Parent) Percentage of shares: 100% (3) Deerfield Private Design Fund IV Number of shares: 1,000 (comprised of shares held by Parent) Percentage of shares: 100% (4) Flynn Number of shares: 1,000 (comprised of shares held by Parent) Percentage of shares: 100%
    (b)
    (1) Deerfield Mgmt IV Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 1,000 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 1,000 (2) Deerfield Management Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 1,000 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 1,000 (3) Deerfield Private Design Fund IV Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 1,000 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 1,000 (4) Flynn Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 1,000 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 1,000 Flynn is the sole member of the general partner of each of Deerfield Mgmt IV and Deerfield Management. Deerfield Mgmt IV is the general partner, and Deerfield Management is the investment manager, of Deerfield Private Design Fund IV. Deerfield Private Design Fund IV is entitled to appoint managers representing a majority of the voting power of the board of managers of Parent.
    (c)
    Except as set forth in Items 3 and 4 of this Schedule 13D, the Reporting Persons have not engaged in any transactions in the Company's securities during the past 60 days.
    (d)
    As a result of the Merger, the Company is a wholly-owned subsidiary of Parent. As of the date of this Schedule 13D, no person other than the Reporting Persons is known to the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock covered by this Schedule 13D, except that a portion of any dividends from, or the proceeds from the sale of, Company Shares held by Parent will be payable to Rollover Stockholders other than Deerfield Private Design Fund IV. As of the date of this Schedule 13D, no Rollover Stockholder (other than Deerfield Private Design Fund IV) is entitled to receive more than 5% of any such dividends or proceeds.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Deerfield Mgmt IV, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-in-Fact
    Date:02/25/2025
     
    Deerfield Private Design Fund IV, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-in-Fact
    Date:02/25/2025
     
    Deerfield Management Company, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-in-Fact
    Date:02/25/2025
     
    James E. Flynn
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-in-Fact
    Date:02/25/2025
    Get the next $OMIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMIC

    DatePrice TargetRatingAnalyst
    8/17/2022$10.00 → $4.50Buy → Neutral
    UBS
    8/10/2022$3.50Buy → Neutral
    Goldman
    8/10/2022$3.00Buy → Underperform
    BofA Securities
    1/7/2022$21.00Neutral → Buy
    BofA Securities
    10/15/2021Outperform
    Cowen
    More analyst ratings

    $OMIC
    SEC Filings

    See more
    • Singular Genomics Systems Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Changes in Control of Registrant

      8-K - Singular Genomics Systems, Inc. (0001850906) (Filer)

      2/27/25 1:42:39 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13D/A filed by Singular Genomics Systems Inc.

      SCHEDULE 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

      2/25/25 9:18:06 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form EFFECT filed by Singular Genomics Systems Inc.

      EFFECT - Singular Genomics Systems, Inc. (0001850906) (Filer)

      2/24/25 12:15:05 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

      SC 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

      11/22/24 7:55:51 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13D filed by Singular Genomics Systems Inc.

      SC 13D - Singular Genomics Systems, Inc. (0001850906) (Subject)

      11/5/24 7:29:21 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

      SC 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

      11/1/24 7:54:29 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Leadership Updates

    Live Leadership Updates

    See more
    • Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors

      SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Marcia Eisenberg, Ph.D., to the Company's Board of Directors. Dr. Eisenberg currently serves as Senior Vice President and Enterprise Chief Scientific Officer at Labcorp (NYSE:LH) and brings more than 30 years of experience with molecular genetics, DNA testing, biotechnology, and molecular oncology. "Marcia's deep and diverse genomics expertise will be an asset to Singular as we drive our business strategy forward, and we are delighted to w

      8/8/23 4:05:00 PM ET
      $LH
      $OMIC
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Appoints Sam Ropp, Ph.D., as Chief Commercial Officer

      SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Sam Ropp, Ph.D., as Chief Commercial Officer. In this role, Dr. Ropp will oversee the company's commercial function, including commercialization of the G4 Sequencing Platform. He will report to Drew Spaventa, Chief Executive Officer and Founder of Singular Genomics. The company also announced the appointment of Jeff Bullard as Head of Sales for North America. "As an accomplished life science leader, Sam brings the deep knowledge and experi

      8/2/22 7:30:00 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Appoints Genomics Research Pioneer Elaine R. Mardis, Ph.D., to Board of Directors

      LA JOLLA, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the addition of Elaine R. Mardis, Ph.D., to the Company's Board of Directors. Dr. Mardis is a pioneering researcher internationally recognized in cancer genomics with a focus on the application of genomic technologies to improve the understanding of human disease and the precision of medical diagnosis, prognosis and treatment. "We are thrilled to have Elaine join the Board of Directors. She brings the rare combination of world-class scientific, indust

      1/6/22 4:05:00 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Financials

    Live finance-specific insights

    See more
    • Singular Genomics Reports Recent Updates and Third Quarter 2024 Financial Results

      SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2024. "In the third quarter, we made significant progress in the development of the G4X spatial sequencer," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "We are encouraged by the interest in the G4X and validation received through the expansion of our Spatial Technology Access Services project funnel, which reinfo

      11/12/24 4:05:00 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Reports Recent Highlights and Second Quarter 2024 Financial Results

      SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the second quarter ended June 30, 2024. "It was another busy and productive quarter for our team as we progressed development of the G4X Spatial Sequencer while supporting our G4 customers," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "The early interest in our Spatial Technology Access Services is an encouraging sign that the unique capabilities and

      8/13/24 4:05:00 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics to Report Second Quarter 2024 Financial Results on August 13, 2024

      SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 13, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 1-888-506-0062 for domestic callers or 1-973-528-0011 for international callers and using conference ID 66

      7/30/24 5:05:42 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tang Kevin returned 372,000 shares to the company (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      2/27/25 8:54:47 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Executive Officer Spaventa Andrew returned 143,310 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      2/25/25 8:12:58 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Financial Officer Meeter Dalen returned 9,502 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      2/25/25 8:11:40 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tang Kevin bought $1,806,220 worth of shares (122,416 units at $14.75) (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      9/18/24 4:31:08 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Spaventa Andrew bought $49,612 worth of shares (118,468 units at $0.42) (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      11/20/23 4:31:38 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Glezer Eli N. bought $85,640 worth of shares (200,000 units at $0.43), increasing direct ownership by 5% to 4,570,000 units (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      11/20/23 4:30:55 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Singular Highlights Key G4X™ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBT

      SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., an innovator in high-throughput spatial multiomics technologies designed to advance precision medicine, today announced key development milestones for its G4X™ Spatial Sequencer at the Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida. G4X Early Access Program Ongoing and Broader Availability on Track The G4X Early Access Program is currently underway at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, providing valuable feedback highlighting the platform's real-world potential. "As the first early access site, we've had the chance to

      2/24/25 8:00:00 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Announces Closing of Acquisition by Deerfield Management

      SAN DIEGO, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today the closing of its acquisition by an affiliate of Deerfield Management Company, L.P.    On December 23, 2024, Singular Genomics announced that Deerfield had signed a definitive agreement to acquire all of the outstanding shares of Singular Genomics common stock not currently owned by Deerfield for $20.00 per share in cash. Following the satisfaction of customary conditions, including a vote of the holders of Singular Genomics' common stock to approv

      2/21/25 9:56:26 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Enters into Agreement to be Acquired by Deerfield for $20.00 in Cash per Share

      SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC) ("Singular Genomics" or the "Company"), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it has entered into a definitive merger agreement whereby an affiliate of Deerfield Management Company, L.P. will acquire Singular Genomics in an all-cash transaction for $20.00 per share. The $20.00 per share represents 254% premium to the last closing share price for Singular's common stock prior to the September 12, 2024 public disclosure of Deerfield's initial acquisition proposal. The Singular Genomic

      12/23/24 8:30:00 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Singular Genomics Systems downgraded by UBS with a new price target

      UBS downgraded Singular Genomics Systems from Buy to Neutral and set a new price target of $4.50 from $10.00 previously

      8/17/22 9:15:00 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Systems downgraded by Goldman with a new price target

      Goldman downgraded Singular Genomics Systems from Buy to Neutral and set a new price target of $3.50

      8/10/22 6:31:06 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Systems downgraded by BofA Securities with a new price target

      BofA Securities downgraded Singular Genomics Systems from Buy to Underperform and set a new price target of $3.00

      8/10/22 6:30:40 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials